Meningiomas are common neoplasms that originate from arachnoid cells. They usually attach to the inner surface of the dura mater. Immunohistochemistry (IHC) can help with their definitive diagnosis. Somatostatin receptors-2A (SSTR-2A) was recently assessed as a potential therapeutic target for the treatment of meningioma. Mucin-4 (MUC4) is overexpressed in various carcinomas, and its expression was reported to correlate with higher tumour progression and worse prognosis. Epithelial membrane antigen (EMA) is highly expressed by most adenocarcinomas, associated with poor prognosis. This study aimed to evaluate the diagnostic value of SSTR-2A, MUC4 as well as EMA in meningiomas and to assess expression of these markers in different grades of meningiomas. Paraffin blocks of 60 selected specimens, diagnosed as different subtypes of meningiomas and 15 paraffin blocks of non-meningioma cases were selected. All specimens underwent immunohistochemical staining for SSTR-2A, MUC4 and EMA expression. There was a strong significant relation between combination of SSTR-2A, EMA and MUC4 in differentiating meningioma from non-meningioma cases (P value <0.05). There was a significant relation between immunoexpression of both SSTR-2A (scoring and intensity) and EMA and the grade of meningioma (p value <0.05). Using a panel of the three markers (SSTR-2A, MUC4 and EMA) is diagnostically superior to using each of which alone in differentiation of meningioma from non-meningioma cases. EMA immunophenotyping is considered the most specific and sensitive marker for meningioma while MUC4 is more specific for meningioma than SSTR-2A but it is less sensitive